Pathophysiological insights in sickle cell disease

Marie-Hélène Odièvre, Emmanuelle Verger, Ana Cristina Silva-Pinto, Jacques Elion, Marie-Hélène Odièvre, Emmanuelle Verger, Ana Cristina Silva-Pinto, Jacques Elion

Abstract

The first coherent pathophysiological scheme for sickle cell disease (SCD) emerged in the sixties-seventies based on an extremely detailed description of the molecular mechanism by which HbS in its deoxy-form polymerises and forms long fibres within the red blood cell that deform it and make it fragile. This scheme explains the haemolytic anaemia, and the mechanistic aspects of the vaso-occlusive crises (VOCs), but, even though it constitutes the basic mechanism of the disease, it does not account for the processes that actually trigger VOCs. This paper reviews recent data which imply: red blood cell dehydration, its abnormal adhesion properties to the endothelium, the participation of inflammatory phenomenon and of a global activation of all the cells present in the vessel, and finally, abnormalities of the vascular tone and of nitric oxide metabolism. These data altogether have shed a new light on the pathophysiology of the first molecular disease i.e. sickle cell disease.

Figures

Fig. 1
Fig. 1
Basic pathophysiological mechanism of sickle cell disease: the polymerization of deoxy-HbS. The replacement of a glutamic acid by a valine residue at position 6 in the β-globin polypeptide chain characterizes the abnormal haemoglobin of SCD: HbS. At low oxygen pressure, deoxy-HbS polymerises and gets organised in long polymer fibres that deform, stiffen, and weaken the red blood cell (not shown). This process represents the basic mechanisms leading to haemolytic anaemia and to vaso-occlusive events in the microcirculation. [Source: Modified from Labie and Elion32].
Fig. 2
Fig. 2
Membrane alterations in the sickle red blood cell. Formation of the deoxy-HbS polymer fibres triggers a whole series of changes of the red blood cell membrane. Ion channels are affected and their dysfunction is responsible for a cellular dehydration which, in a vicious circle, favours deoxy-HbS polymerization. Hemichromes are released and lead, in particular, to the formation of protein band 3 aggregates on which anti-band 3 IgGs accumulate. The liberation of heme and Fe3+ favours an oxidizing microenvironment. Exposure of anionic phosphatidylserines at the external side of the membrane creates a procoagulant surface. Finally, microparticles are released. [Source: Modified and completed from Elion and Labie33].
Fig. 3
Fig. 3
Adhesion of sickle red blood cells to the endothelium and cell activation. Simplified scheme of the main interactions involved in the abnormal adhesion of the sickle red blood cells to the endothelium. Locally, endothelial damage exposes sub-endothelial structures that also participate to the adhesion process. Some adhesion proteins are activated by extracellular stimuli. It is the case of the basal cell adhesion molecule (Lutheran blood group) (Lu/BCAM) that expresses its adhesion properties only when phosphorylated via the protein kinase A-dependent (PKA) pathway when the red blood cell is activated by epinephrine. 2-AR, type 2 adrenergic receptor; Fn, fibronectin; TSP, thrombospondin; Ln, laminin; α4β1, α4β1 integrin (or VLA-4). [Source: Modified from Elion et al34].

References

    1. Pauling L, Itano H, Singer SJ, Wells IC. Sickle cell anemia: a molecular disease. Science. 1949;110:543–8.
    1. Ingram VM. A specific chemical difference between the globins of normal human and sickle-cell anemia haemoglobin. Nature. 1956;178:792–4.
    1. Bunn H, Forget BG. Hemoglobin: Molecular, genetic and clinical aspects. Philadelphia, PA, USA: WB Saunders; 1986.
    1. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med. 1997;337:762–9.
    1. Hebbel RP. Adhesive interactions of sickle erythrocytes with endothelium. J Clin Invest. 1997;100(11 Suppl):S83–6.
    1. Platt OS. Sickle cell anemia as an inflammatory disease. J Clin Invest. 2000;106:337–8.
    1. Hebbel RP. Adhesion of sickle red cells to endothelium: Myths and future directions. Transfus Clin Biol. 2008;15:14–8.
    1. Chiang EY, Frenette PS. Sickle cell vaso-occlusion. Hematol Oncol Clin North Am. 2005;9:771–94.
    1. El Nemer W, Colin Y, Le Van Kim C. Role of Lu/BCAM glycoproteins in red cell diseases. Transfus Clin Biol. 2010;17:143–7.
    1. Rivera A, Jarolim P, Brugnara C. Modulation of Gardos channel activity by cytokines in sickle erythrocytes. Blood. 2002;99:357–603.
    1. Merciris P, Giraud F. How do sickle cells become dehydrated? Hematol J. 2001;2:200–5.
    1. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007;21:37–47.
    1. Edelstein SJ, Telford JN, Crépeau RH. Structure of fibers of sickle cell hemoglobin. Proc Natl Acad Sci USA. 1973;70:1104–7.
    1. Stuart MJ, Nagel RL. Sickle-cell disease. Lancet. 2004;364:1343–60.
    1. Mohandas N, Evans E. Adherence of sickle erythrocytes to vascular endothelial cells: requirement for both cell membrane changes and plasma factors. Blood. 1984;64:282–7.
    1. Elion J, Brun M, Odievre MH, Lapoumeroulie CL, Krishnamoorthy R. Vaso-occlusion in sickle cell anemia: role of interactions between blood cells and endothelium. Hematol J. 2004;5:S195–8.
    1. Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med. 1997;337:1584–90.
    1. Frenette PS, Atweh GF. Sickle cell disease: old discoveries, new concepts, and future promise. J Clin Invest. 2007;117:850–8.
    1. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease.Life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639–44.
    1. Kaul DK, Hebbel RP. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest. 2000;106:411–20.
    1. Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation. 2004;11:129–51.
    1. Piccin A, Murphy WG, Smith OP. Circulating microparticles: pathophysiology and clinical implications. Blood Rev. 2007;21:157–71.
    1. Merciris P, Claussen WJ, Joiner CH, Giraud F. Regulation of K-Cl cotransport by Syk and Src protein tyrosine kinases in deoxygenated sickle cells. Pflugers Arch. 2003;446:232–8.
    1. Durpès MC, Nebor D, du Mesnil PC, Mougenel D, Decastel M, Elion J, et al. Effect of interleukin-8 and RANTES on the Gardos channel activity in sickle human red blood cells: role of the Duffy antigen receptor for chemokines. Blood Cells Mol Dis. 2010;44:219–23.
    1. Hines PC, Zen Q, Burney SN, Shea DA, Ataga KI, Orringer EP, et al. Novel epinephrine and cyclic AMP-mediated activation of BCAM/Lu-dependent sickle (SS) RBC adhesion. Blood. 2003;101:3281–7.
    1. Reiter CD, Gladwin MT. An emerging role for nitric oxide in sickle cell disease vascular homeostasis and therapy. Curr Opin Hematol. 2003;10:99–107.
    1. Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, Sachdev V, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension and mortality in sickle cell disease. JAMA. 2005;294:81–90.
    1. Mack AK, Kato GJ. Sickle cell disease and nitric oxide: a paradigm shift? Int J Biochem Cell Biol. 2006;38:1237–43.
    1. Bunn HF, Nathan DG, Dover GJ, Hebbel RP, Platt OS, Rosse WF, et al. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood. 2010;116:687–92.
    1. Hebbel RP. Reconstructing sickle cell disease: a data-based analysis of the “hyperhemolysis paradigm” for pulmonary hypertension from the perspective of evidence-based medicine. Am J Hematol. 2011;86:123–54.
    1. Hebbel RP, Vercellotti G, Nath KA. A systems biology consideration of the vasculopathy of sickle cell anemia: the need for multi-modality chemo-prophylaxsis. Cardiovasc Hematol Disord Drug Targets. 2009;9:271–92.
    1. Labie D, Elion J. Molecular and cellular pathophysiology of sickle cell anemia. Pathol Biol (Paris) 1999;47:7–12.
    1. Elion J, Labie D. Bases physiopathologiques moléculaires et cellulaires du traitement de la drépanocytose. Hématologie. 1996;2:499–510.
    1. Elion J, Laurance S, Lapouméroulie C. Physiopathologie de la drépanocytose. Med Trop. 2010;70:454–8.

Source: PubMed

3
Abonneren